Consultant Mayo Clinic Rochester, MN, United States
Disclosure(s):
Mabel Ryder, MD: No financial relationships to disclose
Learning Objectives:
Describe how tumor genotype–phenotype characteristics influence iodine avidity in differentiated thyroid cancers and may impact approaches to RAI therapy.
Differentiate the roles of remnant ablation, adjuvant therapy, and therapeutic I 131 in low-, intermediate-, and high-risk DTC based on current evidence and guidelines.
Evaluate emerging strategies—such as MAPK pathway inhibition—for RAI redifferentiation and improved responses to RAI therapy in advanced, metastatic disease.
